July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Subthreshold Micropulse Laser for Treatment of Primary Foveal Telangiectasis Type II
Author Affiliations & Notes
  • John P. McLaughlin
    Krieger Eye Institute at Sinai Hospital of Baltimore, Baltimore, Maryland, United States
  • Bradford Sgrignoli
    National Retina Institute, Towson, Maryland, United States
  • Matthew S J Katz
    National Retina Institute, Towson, Maryland, United States
  • Footnotes
    Commercial Relationships   John McLaughlin, None; Bradford Sgrignoli, None; Matthew Katz, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3155. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John P. McLaughlin, Bradford Sgrignoli, Matthew S J Katz; Subthreshold Micropulse Laser for Treatment of Primary Foveal Telangiectasis Type II. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3155.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Primary Foveal Telangiectasis Type II (PFTII) is a disorder characterized by inner retinal cavitation and abnormalities about the perifoveal vasculature. Treatment options for PFTII are limited. We sought to examine the effects of subthreshold micropulse laser (STMP) as an effective modality to treat vision loss and macular thickening.

Methods : This retrospective chart review followed 7 eyes of 5 patients. Treatment was administered utilizing 810nm laser with standardized parameters of 1.5W at 5% duty cycle, 500µm , and 300ms. Measured endpoints included ETDRS visual acuity (VA), central macular thickness (CMT), and total volume (TV) as measured on optical coherence tomography (OCT). Anatomic metrics were measured on Heidelberg Spectralis OCT (Heidelberg Instruments) and Zeiss Cirrus HD-OCT (Meditec Instruments).
Exclusion criteria were retinal comorbidity, treatment with photocoagulation or intravitreal injection in the preceding 3 months, and the following 6 months.

Results : Of the 7 eyes that met inclusion criteria, each underwent a single laser session, with a mean of 646.4 laser applications per session. Baseline ETDRS visual acuity was 64.1 letters (32-85 letters). Baseline anatomic metrics were: mean CMT of 255.4 µm (157-369µm) and mean TV of 10.1µm (9.0-10.9µm).
At 1 month, of 7 eyes with available data, the mean ΔVA was +3.0 letters, mean ΔCMT of +2.5µm, and no change in mean TV.
At 3 months, of 5 eyes with available data, the mean ΔVA was +4.4 letters, mean ΔCMT of +16.6µm, and mean ΔTV of -0.3µm.
At 6 months, of 5 eyes with available data, the mean ΔVA was +2.2 letters, mean ΔCMT of +8.6µm, and mean ΔTV of +0.1µm.

Conclusions : STMP may be an effective means for retarding and reversing vision loss secondary to PFTII.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×